{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:21:21Z","timestamp":1783660881414,"version":"3.55.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Chronic kidney disease (CKD) is known to increase myocardial infarct size after ischemia\/reperfusion. However, a strategy to prevent the CKD-induced myocardial susceptibility to ischemia\/reperfusion injury has not been developed. Here, we examined whether epoetin \u03b2 pegol, a continuous erythropoietin receptor activator (CERA), normalizes myocardial susceptibility to ischemia\/reperfusion injury by its effects on protective signaling and metabolomes in CKD. CKD was induced by 5\/6 nephrectomy in rats (subtotal nephrectomy, SNx), whereas sham-operated rats served controls (Sham). Infarct size as percentage of area at risk after 20-minutes coronary occlusion\/2-hour reperfusion was larger in SNx than in Sham: 60.0\u00b14.0% versus 43.9\u00b12.2%. Administration of CERA (0.6 \u03bcg\/kg SC every 7 days) for 4 weeks reduced infarct size in SNx (infarct size as percentage of area at risk=36.9\u00b13.9%), although a protective effect was not detected for the acute injection of CERA. Immunoblot analyses revealed that myocardial phospho-Akt-Ser473 levels under baseline conditions and on reperfusion were lower in SNx than in Sham, and CERA restored the Akt phosphorylation on reperfusion. Metabolomic analyses showed that glucose 6-phosphate and glucose 1-phosphate were reduced and malate:aspartate ratio was 1.6-fold higher in SNx than in Sham, suggesting disturbed flux of malate\u2013aspartate shuttle by CKD. The CERA improved the malate:aspartate ratio in SNx to the control level. In H9c2 cells, mitochondrial Akt phosphorylation by insulin-like growth factor-1 was attenuated by malate\u2013aspartate shuttle inhibition. In conclusion, the results suggest that a CERA prevents CKD-induced susceptibility of the myocardium to ischemia\/reperfusion injury by restoration of Akt-mediated signaling possibly via normalized malate\u2013aspartate shuttle flux.<\/jats:p>","DOI":"10.1161\/hypertensionaha.116.07480","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T03:04:02Z","timestamp":1469502242000},"page":"697-706","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Chronic Treatment With an Erythropoietin Receptor Ligand Prevents Chronic Kidney Disease\u2013Induced Enlargement of Myocardial Infarct Size"],"prefix":"10.1161","volume":"68","author":[{"given":"Keitaro","family":"Nishizawa","sequence":"first","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Yano","sequence":"additional","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Tanno","sequence":"additional","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Miki","sequence":"additional","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kuno","sequence":"additional","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Tobisawa","sequence":"additional","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Muratsubaki","sequence":"additional","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Ohno","sequence":"additional","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Miura","sequence":"additional","affiliation":[{"name":"Departments of Cardiovascular, Renal, and Metabolic Medicine (K.N., T.Y., M.T., T.M., A.K., T.T., M.O., S.M., K.O., S.I., T.M.) and Pharmacology (A.K.), Sapporo Medical University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.08.007"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.865352"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000130154.42061.C6"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.055392"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-007-9026-1"},{"key":"e_1_3_3_7_2","first-page":"I","article-title":"Impairment of mTORC2 activation upon reperfusion plays a pivotal role in increased susceptibility to ischemia\/reperfusion in chronic renal failure [Abstract].","volume":"79","author":"Tobisawa T","year":"2015","unstructured":"Tobisawa T, Yano T, Miki T, Tanno M, Kuno A, Kouzu H, Ogasawara M, Muratsubaki S, Nishizawa K, Sugawara H, Ishikawa S, Yoshida H, Miura T. Impairment of mTORC2 activation upon reperfusion plays a pivotal role in increased susceptibility to ischemia\/reperfusion in chronic renal failure [Abstract]. Circ J. 2015;79 (suppl I):I\u20132071.","journal-title":"Circ J"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.247"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004100842"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.473"},{"key":"e_1_3_3_11_2","first-page":"110","article-title":"Pleiotropic functions and tissue-specific expression of erythropoietin.","volume":"16","author":"Sasaki R","year":"2001","unstructured":"Sasaki R, Masuda S, Nagao M. Pleiotropic functions and tissue-specific expression of erythropoietin. News Physiol Sci. 2001;16:110\u2013113.","journal-title":"News Physiol Sci"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.3974"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1535370214523703"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.227.83"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1930406100"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00837.2005"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2008.04925.x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvr302"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.11-196618"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12888"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00325.2015"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000299794"},{"key":"e_1_3_3_23_2","first-page":"306","article-title":"The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.","volume":"67","author":"Provenzano R","year":"2007","unstructured":"Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC; BA 16528 Study Investigators. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol. 2007;67:306\u2013317.","journal-title":"Clin Nephrol"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq206"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvr051"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq205"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13909"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.2009.049452"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.303562"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9137"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M707238200"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112529"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200512100"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.10.1649"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1159\/000109166"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.09.034"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00643.2012"},{"key":"e_1_3_3_38_2","first-page":"CD010590","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.","volume":"8","author":"Palmer SC","year":"2014","unstructured":"Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014;8:CD010590.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2014.08.008"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255448"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.116.07480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:38:33Z","timestamp":1715593113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.116.07480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.116.07480"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.116.07480","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"2016-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}